The Lamb Law Office Newsletter is a monthly communication from our law firm to help keep you up to date with some of the cases that we are working on for clients at the present time. In addition, we provide at least one information resource item per month, which you or someone you know might find helpful from time to time.
Past Newsletter Editions
For your convenience, below we have presented a summary and link for the most recent editions of the Lamb Law Office Newsletter.
July 2023 — In this newsletter, we present information concerning Syfovre is an eye-injection drug treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Syfovre was approved by the FDA in February 2023. Syfovre side effects include occlusive retinal vasculitis, which is a type of eye inflammation that blocks blood flow to the retina resulting in vision loss and could potentially cause blindness. There have also been reported cases of non-occlusive retinal vasculitis and other types of eye inflammation. We are currently investigating Syfovre retinal vasculitis eye inflammation cases as possible Syfovre drug injury lawsuits for patients that would be filed against Apellis Pharmaceuticals, Inc., the drug company responsible for Syfovre. In this newsletter, also, we also point out that hurricane season is upon us, and if you live near the Atlantic Ocean or the Gulf of Mexico, you should keep an eye on these two important hurricane resources if and when there is any pending threat in your area: (1) National Weather Service: Tropical Information; and, (2) National Hurricane Center.
June 2023 — In this newsletter, we set forth the legal basis for Ozempic gallbladder drug injury cases. Essentially, the contention is that the responsible drug company, Novo Nordisk, failed to warn doctors and patients about the risks of gallbladder diseases in a timely manner. In more detail, the contention is that, when one views the March 2022 Ozempic drug label change in the context of what they knew and when they knew it, this Ozempic gallbladder disease warning should have been added earlier. In this newsletter, also, we point out that the Agency for Toxic Substances and Disease Registry (ATSDR) publishes a newsletter about per- and polyfluoroalkyl substances (PFAS) is called PFAS Progress — A Newsletter for Communities. The most recent edition was issued in May 2023.
May 2023 — In this newsletter, we present information concerning a research study whose results were announced in May 2023 found the Camp Lejeune Parkinson’s disease risk was 70% higher when comparing Marines who were stationed at Camp Lejeune at any time from 1975 through 1985 to Marines stationed at Camp Pendleton during that period. The important finding from this new Camp Lejeune medical study is evidence of a significantly increased risk of Parkinson’s disease (PD) associated with exposure to the solvent trichloroethylene (TCE). Veterans and their family members who lived on Camp Lejeune for 30 days or more from 1953 to 1987, and who have been diagnosed with Parkinson’s disease, can have a Camp Lejeune claim filed to get legal compensation. Remember that under the Camp Lejeune Justice Act of 2022, your Camp Lejeune claim must be filed before August 9, 2024. In this newsletter, also, we point out a few resources for severe weather safety from the US Government.
April 2023 — In this newsletter, we identify the medical conditions that are due to past asbestos exposure, namely mesothelioma, lung cancer, and asbestosis. The Law Offices of Thomas J. Lamb has more than 30 years of experience representing people in asbestos and mesothelioma cases. We have been successful in getting our clients legal compensation for their asbestos cancer or asbestos disease in lawsuits and workers’ compensation claims. These cases are handled on a contingency fee basis, meaning that there is no out-of-pocket cost to you at any time while we handle your asbestos or mesothelioma case. And there is no payment to us unless we get a monetary recovery for you. And in this newsletter, we direct you to the latest issue of NIH MedlinePlus Magazine. It includes articles about prosthetic devices and other medical technology, autoimmune diseases, pain, hearing loss, sickle cell disease, and environmental risks to your health. It also has an interview with Anthony Fauci, M.D.
March 2023 – In this newsletter, we explain why firemen are at an increased risk of developing PFAS-related cancers because of their past exposures to PFAS chemicals in the clothes and gear worn by firemen while putting out fires, day after day. The commonly used phrase “turnout gear” refers to pants or trousers, jackets, and boots worn by firefighters when working at an active fire site. We also point out that the Veterans Administration (VA) publication, Military Exposures & Your Health, is now available online four times a year.
February 2023 – In this newsletter, we present information concerning the February 2023 recalls of three over-the-counter eye products due to contamination causing infections, specifically (1) EzriCare Artificial Tears, (2) Delsam Pharma’s Artificial Tears, and (3) Delsam Pharma’s Artificial Eye Ointment, all of which were sold by Global Pharma. We also point out an article about hearing loss that is in the most recent issue of NIH MedlinePlus Magazine. This article includes information about not only hearing loss but also covers the availability of hearing aids.
January 2023 – In this newsletter, we present information concerning some of our various practice areas: Asbestos & Mesothelioma Claims | Benzene Cancer / Disease Claims | Camp Lejeune Water Contamination Cases | GenX Water Contamination Cancer Claims | Pharmaceutical Drug Injury Lawsuits | Breast Implants Lymphoma Cancer Cases. We also point out that a printable version of the most recent issue of NIH MedlinePlus Magazine is now available. This issue features information from NIH on migraines, colorectal cancer, healthy aging, and research on our brain and memory.
November 2022 – In this newsletter, we present information concerning Tepezza, a relatively new drug used primarily for the treatment of Thyroid Eye Disease (TED), and the increasing number of reports about Tepezza hearing-related side effects. We also point out two pharmaceutical drug resources, one of which is an online drug – drug interaction checker and the other being the ConsumerMedSafety.org website.
October 2022 – In this newsletter, we provide some legal representation guidance for those people with Camp Lejeune claims which start with these words of caution: “Do Not Let Anyone Rush You”. We also include an article about the fact that Over-the-Counter (OTC) hearing aids are available now.
September 2022 – In this newsletter, we provide information about Camp Lejeune claims for veterans and their family members who have been diagnosed with various types of cancers. Specifically, we address two “problems” people may be concerned about as regards Camp Lejeune claims involving cancers — that, in fact, are not problems at all, as explained in the featured article. We also include an FDA article about the recently approved COVID-19 bivalent vaccine boosters.
August 2022 – In this newsletter, we report on how to get legal compensation from the United States Government for Camp Lejeune cancer claims. Recent new federal legislation allows former Marines and their family members who lived on Camp Lejeune from 1953 to 1987 for 30 days or more, and who were later diagnosed with cancer, can now file a federal court lawsuit in the Eastern District of North Carolina. The legal basis for these lawsuits is the Camp Lejeune Justice Act of 2022. We also include an FDA article about how to stay safe in the sun.
July 2022 – In this newsletter, we cover the recent findings surrounding the increased incidences of anaplastic large-cell lymphoma (ALCL) associated with breast implants. We also provide information from the National Hurricane Center regarding storm preparation.
June 2022 – In this newsletter, we provide readers with the June 2022 EPA Water Health Advisory for per- and polyfluoroalkyl substances (PFAS). We also cover the litigation surrounding possible GenX water contamination cases.
May 2022 – In this newsletter, we cover the litigation surrounding Benzene, a widely-used chemical known to cause acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). We also provide information regarding medical record copying costs by state.
April 2022 – In this newsletter, we provide readers with a brief overview of our current Asbestos, Benzene, Drug Injury and Breast Implant Lawsuits. We also provide an information resource reporting on every step to simple online security.
March 2022 – In this newsletter, we cover the drug injury litigation regarding the bladder cancer drug, Padcev, and the recent skin reactions involving toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS). We also provide information for ConsumerMedSafety.org, a free online health information resource.
February 2022 – In this newsletter, we cover the drug injury litigation regarding the three types of Mesothelioma in detail, providing background information for the topic. We also provide information for Medline Plus, a free online health information resource.
January 2022 – In this newsletter, we cover the recent side effect warning for Xeljanz, Rinvoq and Olumiant released by the FDA. We also provide readers with an updated information resource addressing COVID-19 self test FAQs and updated isolation and quarantine information.
December 2021 – In this newsletter, we cover the drug injury litigation regarding the recent updates in the Philips CPAP Machines Recall. We also provide readers with an updated information resource addressing COVID-19 vaccine booster shots FAQs.
November 2021 – In this newsletter, we cover bladder cancer drug, Padcev, and the recent skin reactions involving toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS). We also provide readers with an information resource addressing COVID-19 vaccine booster shots FAQs.
October 2021 – In this newsletter, we cover the recent side effect warning for Xeljanz released by the FDA. We also provide readers with an information resource addressing flu vaccine information.
September 2021 – In this newsletter, we provide research resources for drug safety and warnings information. We also provide readers with an information resource regarding FAQs surrounding children and the COVID-19 pandemic.
August 2021 – There was no newsletter sent out for the month of August in 2021.
July 2021 – In this newsletter, we cover the drug injury litigation regarding the recent Philips CPAP Machines Recall. We also provide readers with a new resource with medication safety tips for older adults.
June 2021 – In this newsletter, we cover the drug injury litigation regarding Mesothelioma / Lung Cancer / Asbestosis in detail, providing background information for the topic. We also provide readers with a new resource for Alzheimer’s and related Dementias.
May 2021 – In this newsletter, we provide readers with an information resource regarding hurricane and natural disaster preparedness. We also give readers a brief overview of our firm’s practice areas.
April 2021 – In this newsletter, we provide reader’s with information on how to check your credit report each week for free until 2022. We also provide various legal and medical resources to assist in locating useful, well-presented information.
March 2021 – In this newsletter, we cover three litigations which we are currently handling, Injectafer, Belviq and Ocaliva. We also provide information regarding the American Cancer Society’s Cancer Resource Center.
February 2021 – In this newsletter, we cover three litigations we are currently handling including Xeljanz, Beovu, and Asbestos in Talcum Powder Products. We also provide readers with information regarding individuals’ rights under HIPPA to access their health information.
January 2021 – In this newsletter, we provide readers with a brief overview of our current Drug Injury Lawsuits. We also provide information clarifying the differences between drug interactions, side effects, and allergies. Lastly, there is information from the CDC about the COVID-19 Vaccine.
December 2020 – In this newsletter, we cover the drug injury litigation regarding the SGLT2 Inhibitors class of diabetes drugs (Inovanka, Farxiga, Jardiance, etc.). We also provide information on how to report adverse drug reactions to the FDA MedWatch Program. In addition, we point out the updated CDC Domestic Travel Guidelines.
November 2020 – In this newsletter, we cover two different litigations which we are currently handling, Injectafer and GenX. We also provide information regarding CDC Holiday Gathering Recommendations.
October 2020 – In this newsletter, we cover these three litigation areas: Asbestos – Mesothelioma; Benzene; and, Belviq. We also provide information for Medline Plus, a free online health information resource.
September 2020 – In this newsletter, we cover a few litigations we are currently handling, Breast Implant Devices, Elmiron, and Beovu. We also provide information regarding medical record copying costs by state.
(Last Updated: June 1, 2023)
Newsletter Sign-up Form
You can sign up to receive our monthly newsletter by completing this form.